신경퇴행성 질환 바이오마커 시장 : 전략적 인사이트와 예측(2026-2035년)

The Neurodegenerative Disease Biomarker Market is anticipated to grow at a CAGR of 12.4% from USD 6.18 billion in 2026 to USD 17.67 billion in 2035.

The global neurodegenerative disease biomarker market is experiencing rapid expansion, driven by the increasing prevalence of age-associated neurological disorders and the growing demand for precision medicine. This market encompasses laboratory assays, molecular diagnostic technologies, imaging biomarkers, and analytical platforms that detect biological indicators associated with progressive neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Huntington's disease. Biomarkers provide objective evidence of pathological mechanisms including amyloid deposition, tau aggregation, neuroaxonal injury, neuroinflammation, synaptic dysfunction, and genetic alterations. This capability enables clinicians to differentiate disease subtypes and monitor progression with greater precision. Regulatory authorities and healthcare organizations increasingly recognize biomarkers as essential tools for precision medicine because therapeutic effectiveness depends on accurate identification of disease pathology and progression. Pharmaceutical innovation in disease-modifying therapies is increasing reliance on biomarker-guided clinical trials and companion diagnostics to improve treatment selection and monitor therapeutic response. These structural developments position biomarkers as fundamental components of future neurological diagnosis, drug development, and personalized patient care.

Market Drivers

Growing Adoption of Blood-Based Biomarkers

• Blood-based biomarkers are becoming central to neurodegenerative disease diagnosis because they provide minimally invasive alternatives to cerebrospinal fluid (CSF) analysis while supporting earlier disease detection. Healthcare providers are increasingly incorporating plasma biomarkers such as phosphorylated tau (p-tau), neurofilament light chain (NfL), amyloid-beta (AB), and glial fibrillary acidic protein (GFAP) into diagnostic workflows because these assays improve patient accessibility and clinical scalability. Conventional diagnostic methods often require invasive procedures or expensive imaging, creating demand for laboratory-based alternatives that simplify clinical evaluation. Diagnostic manufacturers are expanding highly sensitive immunoassay technologies capable of delivering standardized analytical performance across diverse healthcare settings. This transition establishes blood-based biomarkers as one of the strongest growth drivers within the market.

Increasing Demand for Precision Neurology

• Precision neurology depends on accurate molecular characterization because neurodegenerative disorders frequently demonstrate overlapping clinical symptoms despite distinct pathological mechanisms. Healthcare providers are increasingly utilizing biomarker-guided diagnosis to improve disease classification and optimize therapeutic decision-making before irreversible neuronal damage progresses. Conventional symptom-based evaluation limits diagnostic confidence, creating demand for objective biological evidence that differentiates disease subtypes. Diagnostic developers are integrating proteomic, genomic, and imaging biomarkers into comprehensive testing platforms that strengthen clinical interpretation. This evolution continues expanding demand for advanced biomarker technologies across neurological healthcare.

Expansion of Disease-Modifying Therapies

• Emerging disease-modifying therapies require validated biomarkers because treatment eligibility increasingly depends on confirmation of underlying disease pathology. Pharmaceutical companies are incorporating biomarker endpoints throughout clinical development to improve patient selection, monitor therapeutic response, and accelerate regulatory approval processes. Healthcare providers require reliable laboratory assays capable of identifying appropriate treatment candidates while supporting longitudinal disease monitoring. Diagnostic companies are responding through development of companion diagnostic platforms that integrate seamlessly into routine clinical practice. These developments reinforce biomarker adoption as therapeutic innovation continues advancing.

Technological Advancements in Biomarker Analysis

• Continuous innovation in proteomics, genomics, multiplex immunoassays, mass spectrometry, and artificial intelligence is improving biomarker sensitivity and analytical reproducibility. Clinical laboratories are increasingly implementing automated platforms because high-throughput technologies enhance operational efficiency while reducing analytical variability. Growing diagnostic complexity creates demand for integrated analytical solutions capable of simultaneously evaluating multiple biomarkers within a single workflow. Technology providers are strengthening digital connectivity and cloud-based analytics that support standardized interpretation across healthcare networks. These innovations continue accelerating adoption of advanced biomarker technologies throughout neurological diagnostics.

Market Restraints

• High analytical validation requirements and lengthy regulatory approval processes delay commercialization of novel biomarker assays. Limited reimbursement coverage for emerging biomarker tests restricts routine clinical adoption across several healthcare systems. Variability in biomarker standardization and inter-laboratory assay performance creates challenges for widespread clinical implementation. Additionally, the high cost of advanced analytical platforms can limit access in resource-constrained settings.

Technology and Segment Insights

By Biomarker Type

• Protein biomarkers constitute the largest segment because they directly reflect pathological processes such as amyloid deposition, tau aggregation, neuroaxonal injury, and neuroinflammation. Healthcare providers are increasingly utilizing biomarkers including phosphorylated tau (p-tau217 and p-tau181), amyloid-beta (AB42/AB40), NfL, and GFAP to improve diagnostic confidence and monitor disease progression. Genetic biomarkers support identification of hereditary risk factors and inherited neurodegenerative syndromes. Metabolic biomarkers provide insights into cellular dysfunction and energy metabolism changes. Inflammatory biomarkers indicate neuroinflammatory processes associated with disease progression. Imaging biomarkers, including amyloid and tau PET tracers, offer complementary structural and functional information. Diagnostic companies are expanding highly sensitive immunoassays and multiplex protein detection platforms that improve analytical precision while supporting routine clinical implementation.

By Disease Indication

• Alzheimer's disease represents the largest disease indication because increasing global prevalence is strengthening demand for accurate early diagnosis and treatment selection. Healthcare providers are increasingly adopting biomarkers such as amyloid-beta, phosphorylated tau, NfL, and GFAP because disease-modifying therapies require pathological confirmation before treatment initiation. Parkinson's disease is the second largest segment, driven by the need for biomarkers that differentiate it from other movement disorders. Multiple sclerosis, ALS, and Huntington's disease represent additional segments requiring specific biomarker solutions. The symptom overlap between various dementias and movement disorders creates diagnostic uncertainty, encouraging broader implementation of biomarker-guided clinical evaluation across all neurodegenerative conditions.

By Sample Type

• Blood represents the fastest-growing sample type because minimally invasive collection improves patient acceptance, enables repeat testing, and supports large-scale screening initiatives. Healthcare providers are increasingly adopting plasma biomarker assays due to their compatibility with routine laboratory workflows and expanding clinical validation. CSF remains important for patients requiring high diagnostic certainty, particularly when blood-based results are inconclusive. Urine, saliva, and tissue samples represent emerging sample types with specific research applications. Diagnostic manufacturers are improving assay performance through advanced detection platforms and standardized analytical protocols. These developments are accelerating the transition toward blood-based precision diagnostics.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic companies and specialized biotechnology firms. Roche Diagnostics differentiates itself through its integrated precision diagnostics ecosystem, combining advanced immunoassay technologies, automated laboratory platforms, and companion diagnostics. The company's Elecsys Amyloid Plasma Panel supports earlier Alzheimer's disease detection while reducing reliance on invasive CSF testing. Fujirebio Holdings specializes in neurological biomarkers with its Lumipulse automated immunoassay platform, including the FDA-cleared Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio assay. Quanterix Corporation is recognized for ultra-sensitive biomarker detection through its Simoa technology, enabling detection of neurological biomarkers at extremely low concentrations. Bio-Techne Corporation provides comprehensive protein analysis technologies, immunoassays, and reagents supporting biomarker discovery and translational research. Abbott Laboratories leverages its global diagnostics infrastructure to support adoption of neurological biomarker testing. Siemens Healthineers integrates laboratory diagnostics, neuroimaging, and digital health technologies into unified precision diagnostic ecosystems. Beckman Coulter provides high-throughput clinical laboratory automation and advanced immunoassay platforms. Sysmex Corporation combines clinical diagnostics, laboratory automation, and molecular technologies.
• Strategic developments include increasing collaborations between diagnostic manufacturers and pharmaceutical companies to develop companion diagnostics aligned with emerging disease-modifying therapies. Companies are investing in multicenter clinical studies to validate blood-based biomarkers against CSF analysis and imaging. Mergers and acquisitions are enabling broader technological portfolios and geographic expansion. Product launches are focused on automated laboratory platforms, multiplex testing systems, and AI-enabled analytical software. Companies that successfully combine advanced biomarker discovery, automated laboratory technologies, and global clinical validation are expected to strengthen their competitive positions.

Conclusion

• The neurodegenerative disease biomarker market is poised for exceptional growth, driven by the increasing prevalence of age-associated neurological disorders and the growing demand for precision medicine. The shift toward blood-based biomarkers, AI-enhanced analytics, and integrated diagnostic platforms is transforming clinical practice. Pharmaceutical innovation in disease-modifying therapies is creating sustained demand for validated biomarkers that support patient selection and treatment monitoring. Companies that successfully combine advanced biomarker discovery, automated laboratory technologies, and global clinical validation are expected to lead the market. Ongoing regulatory support, technological innovation, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Methodology
• 2.5 Assumptions & Limitations

3. Global Neurodegenerative Disease Biomarker Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Biomarker Classification
• 3.4 Market Evolution
• 3.5 Key Market Trends
• 3.6 Historical Market Analysis (2021-2025)
• 3.7 Market Forecast (2026-2035)
• 3.8 Epidemiology and Disease Burden
• 3.9 Biomarker Development Landscape
• 3.10 Clinical Utility and Diagnostic Pathway
• 3.11 Unmet Clinical Needs

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Artificial Intelligence in Biomarker Analysis
• 6.6 Digital Health Integration
• 6.7 Future Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Quality and Compliance Requirements

8. Global Neurodegenerative Disease Biomarker Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Disease Indication
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Technology
• 8.5 Analysis by End User
• 8.6 Analysis by Application

9. Global Neurodegenerative Disease Biomarker Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Protein Biomarkers
  • 9.1.2 Genetic Biomarkers
  • 9.1.3 Metabolic Biomarkers
  • 9.1.4 Inflammatory Biomarkers
  • 9.1.5 Imaging Biomarkers
  • 9.1.6 Other Biomarkers
• 9.2 By Disease Indication
  • 9.2.1 Alzheimer's Disease
  • 9.2.2 Parkinson's Disease
  • 9.2.3 Multiple Sclerosis
  • 9.2.4 Amyotrophic Lateral Sclerosis (ALS)
  • 9.2.5 Huntington's Disease
  • 9.2.6 Other Neurodegenerative Disorders
• 9.3 By Sample Type
  • 9.3.1 Blood
  • 9.3.2 Cerebrospinal Fluid (CSF)
  • 9.3.3 Urine
  • 9.3.4 Saliva
  • 9.3.5 Tissue
  • 9.3.6 Other Sample Types

10. Global Neurodegenerative Disease Biomarker Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Neurodegenerative Disease Biomarker Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers, Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches and Pipeline Progress

13. Company Profiles

• 13.1 Roche Diagnostics
• 13.2 Fujirebio Holdings, Inc.
• 13.3 Quanterix Corporation
• 13.4 Bio-Techne Corporation
• 13.5 Abbott Laboratories
• 13.6 Siemens Healthineers AG
• 13.7 Beckman Coulter, Inc.
• 13.8 Sysmex Corporation
• 13.9 Thermo Fisher Scientific Inc.
• 13.10 Revvity, Inc.
• 13.11 C2N Diagnostics LLC
• 13.12 Quest Diagnostics Incorporated
• 13.13 Laboratory Corporation of America Holdings (Labcorp)
• 13.14 Becton, Dickinson and Company (BD)
• 13.15 Bio-Rad Laboratories, Inc.

14. Global Neurodegenerative Disease Biomarker Market Commercial Forecast Analysis

• 14.1 Protein Biomarkers
• 14.2 Genetic Biomarkers
• 14.3 Metabolic Biomarkers
• 14.4 Inflammatory Biomarkers
• 14.5 Imaging Biomarkers
• 14.6 Other Biomarkers

15. Investment & Funding Analysis

• 15.1 Venture Capital Investments
• 15.2 Government and Public Research Funding
• 15.3 Industry R&D Investments

16. Future Outlook

• 16.1 Emerging Growth Opportunities
• 16.2 Long-Term Industry Trends